RE:RE:RE:RE:RE:Here we go again!As well, both of the directors who will be involved in the new company have pharma backgrounds. It would appear to me that they may be excellent managers etc, but have little background knowledge in Oil and Gas. Just sayin' the Core technology and Aura may still play a part in the company direction. "Time will tell" IMHO.
Guangyu (John) Li, Director, Yangon, Myanmar
John Li is the chief representative of Kunming Pharmaceutical Group (Stock Symbol: 600422) for the Myanmar region. Mr. Li is the CEO of Mican Investment Service Co., Ltd, and is the Vice Secretary General of China Enterprises Chamber of Commerce in Myanmar. John founded the first Wechat Service Account in Myanmar (2014) named "Myanmar Investment" providing local political, economic, and investment related info to Chinese investors. He has extensive experience in the region having lived in Myanmar for 12 years.
Dr. Jake Thiessen, Ph.D, Director, Toronto, Ontario
Dr. Jake J. Thiessen is the Hallman Director, School of Pharmacy, and Director, Health Sciences Campus, University of Waterloo. Jake is a former professor and associate dean at the Leslie Dan Faculty of Pharmacy, University of Toronto. He earned his B.Sc. (Pharm) degree from the University of Manitoba, and went on to complete a M.Sc. at Manitoba and a Ph.D. at the University of California, San Francisco. Jake's area of specialization is pharmacokinetics. His research interests include new approaches in cancer treatment and new molecules to treat patients with iron overload. He has broadened his experience and shared his expertise through work with the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health, Health Canada's Scientific Advisory Committee on Bioavailability and Bioequivalence, and the Canadian Council for Accreditation of Pharmacy Programs.